PTEN and prostate carcinoma: Cima and coworkers followed a two‐stage strategy for biomarker discovery, starting with a discovery scan comparing the serum N‐linked glycoproteome of PTEN conditional knockout model of prostate cancer to wild‐type and then developed targeted assays for 39 human orthologs, which were then quantified in the sera of 143 prostate cancer patients and controls over an abundance range of six orders of magnitude 75.